Key Points

- Beta-lactams are generally safe; allergic and adverse drug reactions are over diagnosed and over reported
- Nonpruritic, nonurticarial rashes occur in up to 10% of patients receiving penicillins. These rashes are usually not allergic and are not a contraindication to the use of a different beta-lactam
- The frequently cited risk of 8 to 10% cross-reactivity between penicillins and cephalosporins is an overestimate based on studies from the 1970’s that are now considered flawed
- Expect new intolerances (i.e. any allergy or adverse reaction reported in a drug allergy field) to be reported after 0.5 to 4% of all antimicrobial courses depending on the gender and specific antimicrobial. Expect a higher incidence of new intolerances in patients with three or more prior medication intolerances
- For type-1 immediate hypersensitivity reactions (IgE-mediated), cross-reactivity among penicillins (table 1) is expected due to similarities in the side chains; risk of cross-reactivity will only be significant between penicillins and cephalosporins with similar side chains
- Only type-1 immediate hypersensitivity to a penicillin manifesting as anaphylaxis, bronchospasm, angioedema, hypotension, urticaria or pruritic rash warrant the avoidance of cephalosporins with similar side chains and other penicillins
- Patients with type-1 immediate hypersensitivity to a penicillin may be safely given cephalosporins with side chains unrelated to the offending agent (See figure 1 & 2 below)
  - For example, ceFAZolin does not share a side chain with any beta-lactam and is not expected to cross react with other agents
- Cross-reactivity between cephalosporins is low due to the heterogeneity between side chains; therefore, a patient with a cephalosporin allergy may be prescribed another cephalosporin with a dissimilar side chain
- Cross-reactivity between penicillins and carbapenems is low. Carbapenems would be a reasonable option when antibiotics are required in patients with type-1 immediate hypersensitivity reaction to penicillins
- Patients with reported Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, immune hepatitis, hemolytic anemia, serum sickness or interstitial nephritis secondary to beta-lactam use should avoid beta-lactams and not receive beta-lactam skin testing, re-challenging or desensitization
- Penicillin skin tests can be used to predict penicillin sensitivity and have a 97-99% negative predictive value
- Any patient with possibility of type-1 immediate hypersensitivity to a beta-lactam should be referred for allergy confirmation

Management of the Beta-Lactam Allergy (Figure 1 & Figure 2) \(^1,2,3,4\)

1. Avoid the unnecessary use of antimicrobials, particularly in the setting of viral infections.
2. Complete a thorough investigation of the patient’s allergies, including, but not limited to: the specific drug the patient received, a detailed description of the reaction, temporal relationship of the onset of the reaction with respect to when the drug was given, concomitant drugs received when the reaction occurred, the time elapsed since the reaction occurred and tolerability of any structurally related compounds. If the patient:
   a. reports intolerance (e.g. nausea, vomiting, diarrhea, headache) – likely not allergic, attempt beta-lactam therapy
   b. has a documented severe non-IgE mediated hypersensitivity reaction to a beta-lactam (e.g. interstitial nephritis, immune hepatitis, hemolytic anemia, serum sickness, severe cutaneous reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), etc...) – avoid all beta-lactam antibiotics including their use for allergy testing, desensitization and re-challenge.
      - Treatment options include non-beta-lactam antibiotics
   c. has a documented severe type-1 immediate (IgE-mediated) hypersensitivity reaction to a penicillin (e.g. anaphylaxis, urticaria, angioedema, hypotension, bronchospasm, stridor, pruritis) – avoid other penicillins and cephalosporins with similar side chains, unless patient undergoes desensitization.
      - Treatment options include cephalosporins with dissimilar side chains, carbapenems, or non-beta-lactam antibiotics – Note: ceFAZolin does not share a side chain with any beta-lactam agent.
   d. has a documented severe type-1 immediate (IgE-mediated) hypersensitivity reaction to a cephalosporin (e.g. anaphylaxis, urticaria, angioedema, hypotension, bronchospasm, stridor, pruritis) – avoid cephalosporins and penicillins with similar side chains (see figure 2) unless desensitization is performed.
      - Treatment options include penicillins or cephalosporins with dissimilar side chains, carbapenems, or non-beta-lactam antibiotics.
Figure 1: Management Diagram

Reported Penicillin Allergy

Assess the nature of the allergy

Onset within 1-72 hours of administration of:
- Anaphylaxis
- Hypotension
- Bronchoconstriction
- Allergic rhinitis
- Early onset urticaria
- Stridor
- Angioedema

Further assess the allergy
- How long ago?
- What specific agent?
- Re-challenged?

Onset after more than 72 hours of administration of:
- Non-pruritic morbilliform rash
- Maculopapular rash

Onset after more than 72 hours of administration of:
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Immune hepatitis
- DRESS
- Serum sickness
- Hemolytic anemia or interstitial nephritis

Avoid testing, desensitizing and re-challenging with all beta-lactam antibiotics

Ok to attempt beta-lactam therapy

Ok to attempt therapy with a different beta-lactam

Penicillin skin testing available?

Yes

Positive Penicillin Skin Test
Avoid all penicillins as well as beta-lactams with a similar side chain (see figure 2) or consider desensitization or select a non-beta-lactam antibiotic

Negative Penicillin Skin test
Consider oral challenge in a monitored setting; if negative, penicillin class antibiotics may be used

No

Convincing history of an IgE-mediated reaction:
Avoid all penicillins as well as beta-lactams with a similar side chain (see figure 2) or consider desensitization or select a non-beta-lactam antibiotic.
Each ‘*’ in the matrix indicates side-chain and/or major/minor antigenic similarity between two antibiotics. For type-1 immediate hypersensitivity there is a risk of cross-allergenicity between pairs due to similar side-chains and/or major/minor antigenic determinants, use NOT recommended without desensitization.

For example: a patient allergic to amoxicillin would likely manifest a reaction to ampicillin, cloxacillin, piperacillin, ticarcillin, cefadroxil, cephalalexin, cefaclor and cefprozil but NOT to ceFAZolin, cefuroxime or cefTRIAXone, etc.

*Please note that the Matrix of Beta-Lactam Cross Allergy should only be used to evaluate the risk of cross-reactivity in patients with type 1 immediate (IgE-mediated) hypersensitivity reactions to a beta-lactam (e.g. anaphylaxis, urticaria, angioedema, hypotension, bronchospasm, stridor, pruritis). Please refer to figure 1 for all other types of reactions.
Table 1: Coombs and Gell Classification of Hypersensitivity Reactions

| Type                          | Mediator                        | Onset                  | Clinical Reaction                                                                 | Comments                                                                 
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>I - Immediate and Acute</td>
<td>IgE antibodies</td>
<td>Less than 1hr (Rarely up to 72 hours)</td>
<td>Anaphylaxis, urticaria, angioedema, hypotension, bronchospasm, stridor, pruritis</td>
<td>Anaphylaxis: Penicillins 0.015 – 0.2% Cephalosporins 0.0001 – 0.1% Avoid the offending agent and side chain related agents (See Figure 2)</td>
</tr>
<tr>
<td>Hypersensitivity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II – Delayed cytotoxic</td>
<td>IgG and IgM antibodies</td>
<td>Greater than 72 hours</td>
<td>Hemolytic anemia, thrombocytopenia, neutropenia</td>
<td>Drug specific, avoid the offending agent</td>
</tr>
<tr>
<td>antibody-mediated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hypersensitivity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III – Antibody complex-</td>
<td>IgG and IgM complexes</td>
<td>Greater than 72 hours</td>
<td>Serum sickness, glomerulonephritis, small vessel vasculitis, drug fever</td>
<td>Antibody-antigen complexes precipitate in tissues and potentially affect any end organ</td>
</tr>
<tr>
<td>mediated hypersensitivity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV – Delayed type</td>
<td>T-Cells</td>
<td>Greater than 72 hours</td>
<td>Contact dermatitis, pustulosis</td>
<td>Incidence is low. Ex: Eosinophilic bullous exanthems, severe exfoliative dermatoses (ex. SJS/TEN), interstitial nephritis, immune hepatitis and some morbilliform or maculopapular rashes</td>
</tr>
<tr>
<td>hypersensitivity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Idiopathic Reactions</td>
<td>Unknown</td>
<td>Usually greater than 72 hours</td>
<td>Maculopapular or morbilliform rashes</td>
<td>1 – 4% of patients receiving beta-lactams Not a contraindication to future use of beta-lactam antibiotics</td>
</tr>
</tbody>
</table>

*Anaphylaxis: defined as serious hypersensitivity reaction that is rapid in onset and may cause death, typically involving the skin, mucosal tissue or both and either respiratory compromise (e.g. dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia) or reduced blood pressure or the associated symptoms and signs of end-organ dysfunction

Table 2: Detailed Allergy History

<table>
<thead>
<tr>
<th>Questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>When did the reaction take place?</td>
</tr>
<tr>
<td>Does the patient recall the reaction? If not, who informed them of the reaction?</td>
</tr>
<tr>
<td>What was the medication prescribed for?</td>
</tr>
<tr>
<td>How long after starting the medication did the reaction begin?</td>
</tr>
<tr>
<td>Did the patient seek medical care due to the reaction?</td>
</tr>
<tr>
<td>Did the patient have any other ongoing medical problem at the time of the reaction?</td>
</tr>
<tr>
<td>Has the patient taken any similar medications before or after the reaction? If so, what was the result?</td>
</tr>
</tbody>
</table>

References: